XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 31, 2022
USD ($)
May 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2019
USD ($)
target
Jul. 01, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Acquired in-process research and development expenses     $ 29,000,000.0 $ 26,700,000   $ 92,900,000 $ 986,800,000    
Verve                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Up-front payment $ 25,000,000                
Purchase of common stock $ 35,000,000                
Catalyst Biosciences                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Asset acquisition, consideration transferred   $ 60,000,000              
CRISPR Therapeutics                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Collaborative arrangement, right to exclusively license, number of targets | target               3  
Collaborative arrangement, development and regulatory potential milestone payments maximum               $ 410,000,000  
CRISPR A&R JDCA                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Collaborative arrangement, development and regulatory potential milestone payments maximum         $ 200,000,000        
Up-front payment         $ 900,000,000        
Allocation of net profits and net losses, percent                 60.00%
CRISPR A&R JDCA | CRISPR                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Allocation of net profits and net losses, percent                 40.00%